Skip to main content

Drug Interactions between paroxetine and Prezista

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

PARoxetine darunavir

Applies to: paroxetine and Prezista (darunavir)

MONITOR: Coadministration with ritonavir- or cobicistat-boosted darunavir may decrease the plasma concentrations of paroxetine. The mechanism of interaction has not been described. In 16 study subjects, administration of paroxetine (20 mg once a day) in combination with darunavir/ritonavir (400 mg/100 mg twice a day) reduced the peak plasma concentration (Cmax), area under the concentration-time curve (AUC), and trough plasma concentration (Cmin) of paroxetine by approximately one-third compared to administration without darunavir/ritonavir. Paroxetine had no significant effect on the pharmacokinetics of darunavir.

MANAGEMENT: Patients treated concomitantly with ritonavir- or cobicistat-boosted darunavir may have diminished clinical response to paroxetine. Pharmacologic response to paroxetine should be monitored more closely whenever darunavir-ritonavir or darunavir-cobicistat is added to or withdrawn from therapy in patients stabilized on their existing antidepressant regimen, and the paroxetine dosage adjusted as necessary.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc
  3. Cerner Multum, Inc. "Australian Product Information."

Switch to consumer interaction data

Drug and food interactions

Moderate

PARoxetine food

Applies to: paroxetine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Moderate

darunavir food

Applies to: Prezista (darunavir)

ADJUST DOSING INTERVAL: Food enhances the absorption and oral bioavailability of darunavir administered in combination with low-dose ritonavir. The mechanism is unknown. When administered with food, the peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of darunavir were approximately 30% higher than when administered in the fasting state. Darunavir exposure was similar for the range of meals studied. The total caloric content of the various meals evaluated ranged from 240 Kcal (12 grams fat) to 928 Kcal (56 grams fat).

MANAGEMENT: To ensure maximal oral absorption, darunavir coadministered with ritonavir should be taken with food. The type of food is not important.

References

  1. (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer